-
Product Insights
![]()
Hyperphosphatemia In Chronic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Report Overview Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus, and rash. Treatment includes phosphate binders and diuretics. The Hyperphosphatemia in chronic kidney disease pipeline...
-
Product Insights
![]()
Hyperphosphatemia Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Hyperphosphatemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperphosphatemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphosphatemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
![]()
Iron Deficiency Anemia Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Iron Deficiency Anemia Global Clinical Trials Review, H2, 2017" provides an overview of Iron Deficiency Anemia clinical trials scenario. This report provides top line data relating to the clinical trials on Iron Deficiency Anemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
![]()
Competitor Landscape: Renal Anemia
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Renal Anemia market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Product Insights
![]()
Hyperphosphatemia Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Hyperphosphatemia Global Clinical Trials Review, H2, 2016" provides an overview of Hyperphosphatemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphosphatemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
![]()
OpportunityAnalyzer: Hyperparathyroidism – Opportunity Analysis and Forecasts to 2025
Hyperparathyroidism (HPT) is a common endocrinal disorder characterised by excessive plasma levels of parathyroid hormone (PTH) stemming from overactivity of the parathyroid glands. The parathyroid glands, of which there are four, regulate physiological calcium homeostasis through a negative feedback mechanism involving PTH secretion. HPT is classified into either primary, secondary, or tertiary, and it is important to differentiate between the three as their underlying aetiology, pathology, and treatment differ. Primary HPT (PHPT), which is characterised by hypercalcemia, results from the...
-
Sector Analysis
![]()
OpportunityAnalyzer: Late – Stage Chronic Kidney Disease – Opportunity Analysis and Forecasts to 2026
The late-stage chronic kidney disease (CKD) - Induced Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia market is expected to undergo significant growth over the next ten years across the seven major markets (7MM) covered in this report (US, France, Germany, Italy, Spain, UK, and Japan). The main driver of this expansion will be the dramatic increase in disease prevalence. According to primary research, GlobalData has determined that there is a high level of unmet need remaining for CKD patients. Despite the launch of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.